Canature Health(SZ:300272) Shenwan Hongyuan Securities·2025-09-25 07:14Investment Rating - The report maintains an "Outperform" rating for the company [1] Core Insights - The company is establishing a wholly-owned subsidiary in the cell industry, aiming to create a second growth curve alongside its existing business [6] - The company has seen growth in its export business, particularly in North America, while domestic sales are being enhanced through a new marketing service model [6] - The gross margin has improved due to increased production scale and digital management [6] - Profit forecasts for 2025 to 2027 indicate significant growth in net profit, with expected increases of 68%, 21%, and 7% respectively [6] Financial Data and Profit Forecast - Total revenue is projected to grow from 1,689 million in 2024 to 2,104 million by 2027, with a compound annual growth rate of approximately 8.2% [5][8] - The net profit attributable to the parent company is expected to rise from 140 million in 2025 to 183 million in 2027, reflecting a strong growth trajectory [5][8] - The company's gross margin is forecasted to stabilize around 39% from 2025 to 2027, indicating consistent profitability [5]